Daratumumab (Dara) Maintenance Therapy Improves Depth Of Response And Results In Durable Progression-Free Survival (Pfs) Following Dara Plus Cyclophosphamide, Bortezomib, And Dexamethasone (Cybord) Induction Therapy In Multiple Myeloma (Mm): Update Of The Lyra Study

Background: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved in combination with bortezomib, melphalan, and prednisone (VMP) and bortezomib and dexamethasone (Vd) for newly diagnosed MM (NDMM) and relapsed MM (RMM), respectively. CyBorD is a commonly used immunomodulatory drug-sparing regimen for MM. In the LYRA (NCT02951819) study, DARA plus CyBorD (DARA-CyBorD) demonstrated efficacy and a tolerable safety profile at the end of induction. Here, we present updated findings examining the effect of monthly DARA maintenance on the efficacy and safety of DARA-CyBorD in NDMM and RMM.